R&D channel feed – Endpoints News

R&D channel feed

GSK’s ViiV stops development of Phase 2 HIV antiviral

7 months ago

Targeting Novartis' Scemblix, Enliven lays out case for leukemia drug in early results

7 months ago

Gritstone bio’s stock dips after it shares more data from failed Phase 2 colorectal cancer trial

7 months ago

Shattuck Labs cuts CD47 program and 40% of workforce as it focuses on IBD drug

7 months ago

IGM scraps oncology work to focus on autoimmune, loses three executives

8 months ago

Poseida shares incremental Phase 1 update for Roche-partnered off-the-shelf CAR-T

8 months ago

Kezar halts mid-stage lupus study after four deaths

8 months ago

Rivus details weight loss data in heart failure patients and preps for new fundraise

8 months ago

Updated: Prime Medicine whittles down pipeline, signs gene editing deal with Bristol Myers

8 months ago

Updated: Roche buys Regor’s CDK inhibitors for $850M upfront amid push to develop 20 ‘transformative’ medicines

8 months ago

Cereno Scientific details mid-stage results for pulmonary arterial hypertension drug

8 months ago

For some multiple myeloma patients, Carvykti cut risk of death by 45%

8 months ago

Travere halts Phase 3 inherited disease trial due to manufacturing scale-up issue

8 months ago

Endpoints 11 winner Xaira Therapeutics: Biotech’s largest AI bet with A-list backers

8 months ago

Genentech's Gazyva hits primary endpoint in late-stage kidney disease trial

8 months ago

A Parkinson's drug that AbbVie acquired from Cerevel succeeds in another Phase 3

8 months ago

Biogen walks away from Sage's essential tremor drug after mid-stage flop, pill's future in question

8 months ago

EnGene unveils first set of pivotal data for NMIBC therapy

8 months ago

Exclusive: J&J folds cardiovascular and metabolic drug unit

8 months ago

Celldex reveals Phase 2 responses for chronic hives drug and higher rates of neutropenia

8 months ago

Novo's semaglutide shows potential in chronic skin condition in obese patients

8 months ago

Merck's LAG-3 plus Keytruda combo fails Phase 3 in colorectal cancer

8 months ago

2seventy bio, Bristol Myers stop late-stage Abecma study in multiple myeloma due to recruitment challenges

8 months ago

Amgen reports dual Phase 3 wins in atopic dermatitis and myasthenia gravis

8 months ago

First page Previous page 24 25 262728 29 30 Next page Last page